Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical

Growth Stage

Own a stake for health equality; affordable and accessible for all

Own a stake for health equality; affordable and accessible for all


Raised this Round: Raised: $312,093

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common



SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Huntington, New York

Business Type


Sen-Jam Pharmaceutical, with a valuation of $70 million, is raising funds on StartEngine. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $9,996 and a maximum target of $3,992,791.95. The campaign proceeds will be used to complete the COVID Phase II trial, seek emergency use authorization, complete the Phase II trial for the alcohol hangover product, and begin the Phase II trial for opioid withdrawal.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 10/12/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Sen-Jam Pharmaceutical 09/14/2024 Wefunder $80,000,000 $1,314,628 Convertible Note Active RegCF
Sen-Jam Pharmaceutical 01/05/2024 Self Managed - - Convertible Note Funded RegD 506(c)
Sen-Jam Pharmaceutical 01/10/2023 StartEngine $69,979,019 $312,093 Equity - Common Funded RegCF
Sen-Jam Pharmaceutical 07/30/2022 Wefunder $25,000,000 $1,008,951 Convertible Note Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Add to portfolio
Sen-Jam Pharmaceutical on StartEngine 2022
Platform: StartEngine
Security Type: Equity - Common
Valuation: $69,979,019
Price per Share: $7.35

Follow company

Follow Sen-Jam Pharmaceutical on StartEngine 2022

Buy Sen-Jam Pharmaceutical's Deal Report

Warning: according to the close date for this deal, Sen-Jam Pharmaceutical may no longer be accepting investments.

Sen-Jam Pharmaceutical Deal Report

Get KingsCrowd’s comprehensive report on Sen-Jam Pharmaceutical including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Sen-Jam Pharmaceutical is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Sen-Jam Pharmaceutical deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge